The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Cogent Biosciences Inc shares valued at $24,999,993 were purchased by Fairmount Funds Management LLC on Jul 10 ’25. At $9.00 per share, Fairmount Funds Management LLC acquired 2,777,777 shares. The insider’s holdings grew to 9,003,418 shares worth approximately $103.81 million following the completion of this transaction.
Also, Pinnow Cole purchased 43,750 shares, netting a total of over 332,412 in proceeds. Following the buying of shares at $7.60 each, the insider now holds 45,848 shares.
As published in their initiating research note from Scotiabank on March 07, 2025, Cogent Biosciences Inc [COGT] has been a Sector outperform and the price target has been revised to $17. Analysts at Needham downgraded the stock from ‘”a Buy”‘ to ‘”a Hold”‘ outlook in a report released in mid December. As of February 26, 2024, Robert W. Baird has decreased its “an Outperform” rating to a “Neutral” for COGT. Earlier on February 08, 2024, Citigroup initiated its rating. Their recommendation was “a Buy” for COGT stock.
Analyzing COGT Stock Performance
On last trading session,, Cogent Biosciences Inc [NASDAQ: COGT] plunged -2.62% to $11.53. The stock’s lowest price that day was $11.51, but it reached a high of $12.105 in the same session. During the last five days, there has been a drop of approximately -6.79%. Over the course of the year, Cogent Biosciences Inc shares have jumped approximately 21.11%.
Support And Resistance Levels for Cogent Biosciences Inc (COGT)
RSI (Relative Strength Index) is 66.77 on the 14-day chart, showing neutral technical sentiment.
Is Cogent Biosciences Inc subject to short interest?
Stocks of Cogent Biosciences Inc saw a sharp steep in short interest on 2025-07-15 dropping by -2.76 million shares to 13.76 million. Data from Yahoo Finance shows that the short interest on 2025-06-13 was 16.52 million shares. A decline of -20.08% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 2.76 of the overall float, the days-to-cover ratio (short ratio) decline to 2.76.
Which companies own the most shares of Cogent Biosciences Inc (COGT)?
In terms of Cogent Biosciences Inc share price expectations, FactSet research, analysts set an average price target of 17.5 in the next 12 months, up nearly 47.8% from the previous closing price of $11.84. Analysts anticipate Cogent Biosciences Inc stock to reach 24 by 2025, with the lowest price target being 14. In spite of this, 4 analysts ranked Cogent Biosciences Inc stock as Buy at the end of 2025. On December 11, 2023, Wedbush assigned a price target of “a Neutral” to the stock and downgraded coverage with a $5.
